Sloan-Kettering Institute for Cancer Research

General Electric Company

Memorial Sloan Kettering Cancer Center

Other

Ariad Gene Therapeutics, Inc.

Sloan-Kettering Institute for Cancer

Certara USA, Inc.

James Edward Rothman

Mee H Hoe

Mark Mayhew

Alan N Houghton

Yoshizumi Takeuchi

F Ulrich Hartl

Hae Won Lim

John Donald Burczak

Yoshizumi Takechi

Anup Sood

Lisa Anne Lowery

Praveena Mohan

Dino De Angelis

Franz-Ulrich Hartl

Franz Ulrich Hartl

Christopher Michael Puleo

Paul Michael Smigelski, Jr

Erik Leeming Kvam

Victoria Eugenia Cotero

Robert Scott Duthie

Kenneth Wayne Rigby

Cynthia Elizabeth Landberg Davis

Craig Patrick Galligan

Jason William Castle

Timothy P Clackson

Gregory Andrew Grossman

Gero Miesenböck

Victor M Rivera

Gero Miesenb&ouml;ck

The present invention relates to a microbubble complex comprising a microbubble having an outer shell comprising a mixture of native and denatured albumin encapsulating a perfluorocarbon gas, a therapeutic agent, a bifunctional linker having one end attached to the therapeutic agent and the other attached to a ligand and wherein the ligand is bound to the other shell of the microbubble through hydrophobic interactions. Also included are methods for delivering the aforementioned microbubble complex to a tissue target.

Microbubble complexes and methods of use

A separation device, system and associated method are provided herein for separation of particulates form a base fluid. The separation device comprises a first microchannel comprising a fluid inlet and a mesofluidic collection chamber. The mesofluidic collection chamber has a first side and a second side, wherein the mesofluidic collection chamber is operatively coupled to the first microchannel on the first side, and wherein the mesofluidic collection chamber comprises a first fluid outlet at the second side, such that the fluid inlet, first microchannel, and first fluid outlet are in fluidic communication via the mesofluidic collection chamber.

Devices for separation of particulates, associated methods and systems

The present invention relates to functionally closed systems for mixing and delivering microbubble pharmaceuticals. Described is a device comprising a rigid outer layer and a flexible bladder wherein mixing occurs using external mixing sources. Also included is a system for dispensing the pharmaceuticals to its end use after mixing. Methods for mixing and dispensing microbubble pharmaceuticals are also described.

System for mixing and dispersing microbubble pharmaceuticals

The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of at least one heat shock protein in combination with one or more defined target antigens. These methods and compositions may be used in the treatment of infectious eases and cancers.

Heat shock protein-based vaccines and immunotherapies

The invention relates to methods and compositions which utilize the emission of light to monitor changes in microenvironments involving cells. The invention is especially useful for monitoring exocytotic activity such as detecting quantal release of synaptic vesicles. Fusion proteins ofand synaptotagmin-I or VAMP/synaptobrevin-2 were targeted to synaptic vesicles and, upon exocytosis, formed light-emitting complexes with luciferin present in the extracellular medium. Photon emissions in the presence of a depolarizing stimulus can be observed with these systems. pH-sensitive mutants of green fluorescent protein are also provided, which are useful for visualizing exocytosis and for imaging and measuring the pH of intracellular compartments.

Hybrid molecules and their use for optically detecting changes in cellular microenvironments

The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of a heat shock protein complexed to a hybrid antigen comprising an antigenic domain and a heat shock protein-binding domain. These methods and compositions may be used in the treatment of infectious diseases and cancers.

The invention relates to methods and compositions which utilize the emission of light to monitor changes in microenvironments involving cells. The invention is especially useful for monitoring exocytotic activity such as detecting quantal release of synaptic vesicles. Fusion proteins of Cypridina luciferase and synaptotagmin-I or VAMP/synaptobrevin-2 were targeted to synaptic vesicles and, upon exocytosis, formed light-emitting complexes with luciferin present in the extracellular medium. Photon emissions in the presence of a depolarizing stimulus can be observed with these systems. pH-sensitive mutants of green fluorescent protein are also provided, which are useful for visualizing exocytosis and for imaging and measuring the pH of intracellular compartments.

The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of at least one heart shock protein in combination with one or more defined target antigens. These methods and compositions may be used in the treatment of infectious diseases and cancers.

The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of at least one heat shock protein in combination with one or more defined target antigens. These methods and compositions may be used in the treatment of infectious diseases and cancers.

Administration of expressible polynucleotides encoding eukaryotic heat shock proteins to mammalian cells leads to the stimulation of an immune response to antigens present in those cells. This makes it possible to stimulate an immune response to target antigens, including target tumor antigens or antigens associated with an infectious disease, without having to isolate a unique antigen or antigen-associated heat shock protein for each target antigen by administering to a mammalian subject or to a group of mammalian cells containing the antigen, an expressible polynucleotide encoding a heat shock protein. The expressed heat shock protein may have the same structure as native heat shock proteins, or may have a modified form adapted to control the trafficking of the expressed heat shock protein within the cells.

Method of treatment of cancer and infectious disease and compositions useful in same

Growing community of inventors

New York, NY, United States of America

James Edward Rothman